A joint model for the kinetics of CTC count and PSA concentration during treatment in metastatic castration-resistant prostate cancer

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 5, 2015, Pages 277-285

  Wilbaux, M ^a   Tod, M ^a   De Bono, J ^b   Lorente, D ^b   Mateo, J ^b   Freyer, G ^a,c   You, B ^a,c   Henin E ^a  

^a UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BINOMIAL DISTRIBUTION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; DISEASE MARKER; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84936743694     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.34     Document Type: Article

References (37)

1. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., &, Forman, D., Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. Bubendorf, L., et al,. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578-583 (2000).
3. Scher, H.I., et al,. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148-1159 (2008).
4. Wang, M.C., Valenzuela, L.A., Murphy, G.P., &, Chu, T.M., Purification of a human prostate specific antigen. Invest. Urol. 17, 159-163 (1979).
5. Almufti, R., et al,. A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann. Oncol. 25, 41-56 (2014).
6. Petrylak, D.P., et al,. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst. 98, 516-521 (2006).
7. Allard, W.J., et al,. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897-6904 (2004).
8. Ashworth, T.R., A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med. J. Aust. 14, 146-147 (1869).
9. Tibbe, A.G., Miller, M.C., &, Terstappen, L.W., Statistical considerations for enumeration of circulating tumor cells. Cytometry A 71, 154-162 (2007).
10. Liberko, M., Kolostova, K., &, Bobek, V., Essentials of circulating tumor cells for clinical research and practice. Crit. Rev. Oncol. Hematol. 88, 338-356 (2013).
11. Cohen, S.J., et al,. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 3213-3221 (2008).
12. Cristofanilli, M., et al,. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791 (2004).
13. de Bono, J.S., et al,. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302-6309 (2008).
14. Goldkorn, A., et al,. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J. Clin. Oncol. 32, 1136-1142 (2014).
15. Scher, H.I., et al,. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J. Clin. Oncol. 29, 293s (suppl; abstract LBA4517) (2011).
16. Coumans, F.A., Ligthart, S.T., &, Terstappen, L.W., Interpretation of changes in circulating tumor cell counts. Transl. Oncol. 5, 486-491 (2012).
17. Scher, H.I., et al,. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 10, 233-239 (2009).
18. Bock, J.L., &, Klee, G.G., How sensitive is a prostate-specific antigen measurement? How sensitive does it need to be? Arch. Pathol. Lab. Med. 128, 341-343 (2004).
19. Beal, S.L., Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28, 481-504 (2001).
20. Bonate, P.L., &, Suttle, A.B., Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. Cancer Chemother. Pharmacol. 72, 231-240 (2013).
21. Ribba, B., et al,. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacometrics Syst. Pharmacol. 3, e113 (2014).
22. Krzyzanski, W., &, Perez Ruixo, J.J., Lifespan based indirect response models. J. Pharmacokinet. Pharmacodyn. 39, 109-123 (2012).
23. Plan, E.L., Maloney, A., Trocõniz, I.F., &, Karlsson, M.O., Performance in population models for count data, part I: maximum likelihood approximations. J. Pharmacokinet. Pharmacodyn. 36, 353-366 (2009).
24. Beal, S.L., Sheiner, L.B., Boeckmann, A., &, Bauer, R.J., NONMEM user's guides (1989-2009) (Ellicott City, MD: Icon Development Solutions, 2009).
25. Perez-Ruixo, J.J., Kimko, H.C., Chow, A.T., Piotrovsky, V., Krzyzanski, W., &, Jusko, W.J., Population cell life span models for effects of drugs following indirect mechanisms of action. J. Pharmacokinet. Pharmacodyn. 32, 767-793 (2005).
26. Jonsson, E.N., &, Karlsson, M.O., Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58, 51-64 (1999).
27. Lindbom, L., Ribbing, J., &, Jonsson, E.N., Perl-speaks-NONMEM (PsN) - A Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75, 85-94 (2004).
28. R Development Core Team. R: a language and environment for statistical computing. (Vienna, Austria, R Foundation for Statistical Computing, 2010).
29. [No authors listed]. Guidance for industry on population pharmacokinetics; availability. Food and Drug Administration, HHS. Notice. Fed. Regist. 64, 6663-6664 (1999).
30. Yano, Y., Beal, S.L., &, Sheiner, L.B., Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J. Pharmacokinet. Pharmacodyn. 28, 171-192 (2001).
31. Jacqmin, P., et al,. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J. Pharmacokinet. Pharmacodyn. 34, 57-85 (2007).
32. Dayneka, N.L., Garg, V., &, Jusko, W.J., Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21, 457-478 (1993).
33. Emmenegger, U., &, Ko, Y.J., PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations. Can. Urol. Assoc. J. 3, 375-376 (2009).
34. Meng, S., et al,. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152-8162 (2004).
35. Stott, S.L., et al,. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci. Transl. Med. 2, 25ra23 (2010).
36. Kim, M.Y., et al,. Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326 (2009).
37. Kola, I., &, Landis, J., Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).